Tilray Brands, Inc. (TLRY) Suffers a Larger Drop Than the General Market: Key Insights

Tilray Brands, Inc. (TLRY) closed the most recent trading day at $7.20, moving -2.04% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.35%. At the same time, the Dow lost 0.45%, and the tech-heavy Nasdaq lost 0.14%. The stock of company has fallen by 40.73% in the past month, lagging the Medical sector's gain of 5.67% and the S&P 500's gain of 1.2%.Investors will be eagerly watching for the performance of Tilray Brands, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.17, showcasing a 83% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $209.65 million, indicating a 0.62% downward movement from the same quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.45 per share and revenue of $867.01 million, indicating changes of -550% and +4.88%, respectively, compared to the previous year. Investors might also notice recent changes to analyst estimates for Tilray Brands, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Tilray Brands, Inc. currently has a Zacks Rank of #2 (Buy). The Medical - Products industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 155, finds itself in the bottom 38% echelons of all 250+ industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. To follow TLRY in the coming trading sessions, be sure to utilize Zacks.com. Zacks Naming Top 10 Stocks for 2026Want to be tipped off early to our 10 top picks for the entirety of 2026? History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s +570.3%.Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2026. Don’t miss your chance to get in on these stocks when they’re released on January 5. Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tilray Brands, Inc. (TLRY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks